KANSAS AND 16 OTHER STATES MOVE TO JOIN SUITS AGAINST PHARMACEUTICAL GIANT WYETH

KANSAS AND 16 OTHER STATES MOVE TO JOIN SUITS AGAINST PHARMACEUTICAL GIANT WYETH

May 10, 2010 -- On Friday, Kansas and sixteen other states, including Colorado, Kentucky, Maine, Maryland, Minnesota, Nebraska, New Jersey, North Carolina, Oregon, Rhode Island, South Carolina, South Dakota, Utah, Vermont, Washington and Wyoming, filed a joint motion for leave to intervene in two whistleblower lawsuits against the drug manufacturer Wyeth alleging that the company knowingly failed to report certain discounted prices of its drugs as required by laws governing the Medicaid program. As a result, Wyeth allegedly avoided paying hundreds of millions in rebates due to state Medicaid programs for its drugs, Protonix Oral and Protonix IV.  These drugs belong to a class of drugs known as proton pump inhibitors (PPI), which are used to suppress stomach acid.

Under the Medicaid Drug Rebate Program, drug manufacturers are required to report to the government certain prices they charge their customers, including the "best price" offered for their drugs.  They also are required to pay rebates to the state Medicaid programs which are calculated based on the reported discounted prices offered to other customers.  Congress created the Medicaid Drug Rebate Program in order to ensure that Medicaid, the nation's provider of health insurance to the poor and the disabled and one of the largest purchasers of drugs, receive the benefit of the same discounts offered to other large commercial customers in the marketplace.

Between 2001 and 2006, Wyeth offered steep discounts to thousands of hospitals nationwide for Protonix Oral and Protonix IV under pricing arrangements known as "Protonix Performance Agreements" that offered discounted prices based on certain conditions, such as market share or placement on formularies.  The States allege that Wyeth was required under the Medicaid Drug Rebate Program to report these prices paid by hospitals under this arrangement, and to pass along the benefit of the lower prices to the state Medicaid programs. Wyeth allegedly failed to do so and therefore avoided paying hundreds of millions of dollars to Medicaid in rebates.

"The best price reporting requirement was enacted by Congress to ensure Medicaid programs are treated equally by drug companies," said Attorney General Six.  "We are alleging Wyeth offered massive discounts to certain customers then concealed that information from Medicaid, costing the Kansas Medicaid program much more for these drugs than the law allows."

The case is being handled by the Kansas Office of Attorney General, Medicaid Fraud and Abuse Division.  Last May, the United States and 16 other named plaintiff states intervened in these two whistleblower lawsuits now pending in the United States District Court for Massachusetts.  By intervening in the suits, Kansas seeks damages from Wyeth on behalf of its Medicaid program.

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.